CAR t cell therapy: 15-Year safety check begins for lymphoma patients

NCT ID NCT04911478

Ongoing Knowledge-focused Sponsor: Adicet Therapeutics Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated May 14, 2026 · Updated 5 times

Summary

This study follows about 50 people who have already received an experimental CAR T cell therapy for certain types of lymphoma. The goal is to track any long-term side effects and survival for up to 15 years after treatment. No new study drug is given, but participants may receive other cancer treatments during follow-up.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Baylor Scott & White Research Institute

Dallas, Texas, 75204, United States
Blood and Marrow Transplant Program

Palo Alto, California, 94304, United States
MD Anderson Caner Center

Houston, Texas, 77030, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA LYMPHOMA, FOLLICULAR LYMPHOMA, MANTLE-CELL LYMPHOMA,NON-HODGKIN MARGINAL ZONE LYMPHOMA MARGINAL ZONE LYMPHOMA PRIMARY MEDIASTINAL B-CELL LYMPHOMA